Mayo Clinic researchers conducted a randomized, double-blind Phase II study involving patients with type 2 diabetes and found that those who received the oral hepatoselective glucokinase activator TTP399 had a clinically significant and sustained A1C reduction from baseline, compared with those on placebo. The findings in Science Translational Medicine also revealed that those who received TTP399 at 800 mg/day had reduced fasting plasma glucagon, increased HDL cholesterol, and reduced weight among patients weighing at least 100 kg.